Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:EGRXNASDAQ:KZIANYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.16-0.9%$1.29$0.85▼$4.40$37.65M0.2531,359 shs29,569 shsEGRXEagle Pharmaceuticals$2.90+7.4%$2.10$1.50▼$2.95$37.66M0.838,835 shs7,821 shsKZIANovogen$6.34-2.9%$4.96$2.86▼$79.00$6.58M2.48384,355 shs60,192 shsVORVor Biopharma$1.06+19.1%$0.36$0.13▼$1.80$132.46M-0.513.63 million shs48.67 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-0.93%+2.67%-10.84%-8.73%-57.39%EGRXEagle Pharmaceuticals+7.41%+0.87%+52.63%+229.55%-41.06%KZIANovogen-2.91%-30.71%+78.09%+44.07%-39.24%VORVor Biopharma+19.10%+341.12%+497.18%+40.79%-7.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari Therapeutics1.5271 of 5 stars0.05.00.00.02.03.30.0EGRXEagle Pharmaceuticals2.2117 of 5 stars0.03.00.03.90.03.30.0KZIANovogen2.9773 of 5 stars3.52.00.00.03.30.00.0VORVor Biopharma3.9101 of 5 stars4.35.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AKZIANovogen 3.00Buy$57.50806.94% UpsideVORVor Biopharma 2.50Moderate Buy$7.06565.77% UpsideCurrent Analyst Ratings BreakdownLatest KZIA, VOR, EGRX, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $0.40(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.15$7.25 per share0.40N/A∞KZIANovogen$1.51M4.24N/AN/A($9.87) per share-0.64VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-213.59%-65.60%8/18/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AKZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/AVORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.160.16EGRXEagle PharmaceuticalsN/AN/AN/AKZIANovogenN/A0.21N/AVORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%EGRXEagle Pharmaceuticals85.36%KZIANovogen30.89%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%EGRXEagle Pharmaceuticals28.90%KZIANovogen1.00%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million19.92 millionNot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataKZIANovogen121.01 million997,000OptionableVORVor Biopharma140124.96 million65.45 millionNot OptionableKZIA, VOR, EGRX, and AKTX HeadlinesRecent News About These CompaniesVor Biopharma (NYSE:VOR) Gains Momentum S&P 5005 hours ago | kalkinemedia.comKVor Biopharma Inc. Stock Grades - Barron'sJune 27 at 4:06 PM | barrons.comVor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJune 27 at 10:31 AM | marketbeat.comVor, with new CEO, changes course to target autoimmune diseaseJune 26 at 8:41 PM | biopharmadive.comBAfter axing 95% workforce, Vor bets $4B+ on Remegen’s telitaciceptJune 26 at 8:41 PM | bioworld.comBVor Biopharma Insider Trading Activity | NASDAQ:VOR | BenzingaJune 26 at 3:39 PM | benzinga.comVor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactionsJune 26 at 3:39 PM | fiercepharma.comFVor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune TherapyJune 26 at 3:39 PM | msn.comVor Biopharma Target of Unusually High Options Trading (NYSE:VOR)June 26 at 11:31 AM | marketbeat.comVor Biopharma: Vor Bio Announces $175 Million Private PlacementJune 26 at 10:37 AM | finanznachrichten.deVor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetJune 26 at 10:37 AM | finanznachrichten.deVor Biopharma stock soars after licensing deal for autoimmune therapyJune 26 at 10:37 AM | investing.comWedbush Reaffirms "Neutral" Rating for Vor Biopharma (NYSE:VOR)June 26 at 10:00 AM | marketbeat.comVor Bio Announces $175 Million Private PlacementJune 25 at 5:03 PM | globenewswire.comVor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetJune 25 at 4:45 PM | globenewswire.comEstimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)June 25 at 1:59 PM | finance.yahoo.comVor Biopharma Stock Price History - Investing.comJune 24, 2025 | investing.comVor Biopharma Inc. (VOR) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comVor Bio details extent of Cambridge layoffs in state filingJune 2, 2025 | bizjournals.comCambridge biotech company researching blood cancers to close, lay off 155June 2, 2025 | masslive.comMVor Biopharma Inc. Advanced Charts - Barron'sMay 29, 2025 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceWhich Analyst-Favorite Drone Stock Will Come Out on Top?By Nathan Reiff | June 25, 2025View Which Analyst-Favorite Drone Stock Will Come Out on Top?3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeBy Nathan Reiff | June 9, 2025View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomTop 3 FOMO Stocks for 2025 With More Room to RunBy Dan Schmidt | June 9, 2025View Top 3 FOMO Stocks for 2025 With More Room to RunKZIA, VOR, EGRX, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.16 -0.01 (-0.93%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$1.16 +0.00 (+0.08%) As of 06/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Eagle Pharmaceuticals NASDAQ:EGRX$2.90 +0.20 (+7.41%) As of 06/27/2025 03:57 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Novogen NASDAQ:KZIA$6.34 -0.19 (-2.91%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$6.35 +0.01 (+0.22%) As of 06/27/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Vor Biopharma NYSE:VOR$1.06 +0.17 (+19.10%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.04 -0.02 (-1.42%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
